(Q35143274)

6 August 2017

title

Hepatitis vaccines: recent advances (English)

1 reference

6 August 2017

Raymond S Koff

1

1 reference

6 August 2017

publication date

1 May 2003

1 reference

International Journal for Parasitology

6 August 2017

published in

1 reference

6 August 2017

volume

33

1 reference

6 August 2017

issue

5-6

1 reference

6 August 2017

page(s)

517-523

1 reference

Vaccination against hepatitis A in children aged 12 to 24 months [corrected].

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Magnitude and quality of antibody response to a combination hepatitis A and hepatitis B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Immunogenicity and protectivity of a new liposomal hepatitis A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Implementation of vaccination in patients with cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Hepatitis B vaccination and the risk of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Control of hepatitis A through routine vaccination of children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Response to HBV vaccine in relation to vaccine dose and anti-HCV positivity: a New South Wales correctional facilities' study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Variants of two major T cell epitopes within the hepatitis B surface antigen are not recognized by specific T helper cells of vaccinated individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Efficient initiation of HCV RNA replication in cell culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

DNA vaccines for hepatitis C virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Studies of hepatitis C virus in chimpanzees and their importance for vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Comparative immunogenicity and safety of two dosing schedules of a combined hepatitis A and B vaccine in healthy adolescent volunteers: an open, randomised study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Membrane fusion induced by a lipopeptidic epitope from VP3 capside protein of hepatitis A virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Vaccination of chimpanzees against infection by the hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Cost analysis of two strategies for hepatitis A vaccination of hospital health-care personnel in an intermediate endemicity area

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Hepatitis B vaccinees may be mistaken for confirmed hepatitis B surface antigen-positive blood donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Recombinant vaccines for hepatitis E.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Lack of Protective Immunity Against Reinfection with Hepatitis C Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Vaccination against hepatitis delta virus infection: studies in the woodchuck (Marmota monax) model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

A randomized study of a flexible booster dosing regimen of VAQTA in adults: safety, tolerability, and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

DNA-Based immunization produces Th1 immune responses to hepatitis delta virus in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Perspectives: towards a peptide-based vaccine against hepatitis C virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Are we giving too many doses of hepatitis A and B vaccines?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Detection of antibodies to HAV 3C proteinase in experimentally infected chimpanzees and in naturally infected children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Superinfection of heterologous hepatitis C virus in a patient with chronic type C hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Mutations in Hepatitis C Virus RNAs Conferring Cell Culture Adaptation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Development of a plant-derived subunit vaccine candidate against hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

A new accelerated vaccination schedule for rapid protection against hepatitis A and B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination programme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Efficacy and limitations of a specific immunotherapy in chronic hepatitis B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Four chimpanzee monoclonal antibodies isolated by phage display neutralize hepatitis a virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

The first five years of universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 5-year-olds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

The role of child care in a community-wide outbreak of hepatitis A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

H2 strain attenuated live hepatitis A vaccines:protective efficacy in a hepatitis A outbreak.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900065-1

10.1016/S0020-7519(03)00065-1

7 January 2021

Identifiers

DOI

1 reference

6 August 2017

1 reference